Researchers examined the evidence on the health effects of the use of gaseous fuels for heating and cooking in various countries.
argenx wins EMA CHMP nod for subcutaneous Vyvgart in myasthenia gravis – Pharmaceutical Technology
Vyvgart is argenx’s high-grossing drug, having generated $269m in Q2 2023. Image Credit: Kateryna Kon / Shutterstock. The Committee for Medicinal Products for Human Use